Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria.
Department of Cardiology, Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, Switzerland.
Diabetes Obes Metab. 2016 Oct;18(10):1006-12. doi: 10.1111/dom.12709. Epub 2016 Jul 28.
To investigate the efficacy of vitamin D supplementation on glycaemic control.
The Styrian Vitamin D Hypertension Trial was a single-centre, double-blind, placebo-controlled study conducted between 2011 and 2014 at the Medical University of Graz, Austria. We enrolled 200 people with arterial hypertension and 25-hydroxyvitamin D [25(OH)D] concentrations <30 ng/mL. Study participants were randomized to receive either 2800 IU of vitamin D or placebo per day for 8 weeks. The present study was a post hoc analysis that incorporated an analysis of covariance (ancova) approach, while adjusting for baseline differences.
A total of 185 participants [mean ± standard deviation age, 60.1 ± 11.3 years; 47% women; mean 25(OH)D 21.2 ± 5.6 ng/mL, mean glycated haemoglobin (HbA1c) 44.8 ± 11.8 mmol/mol and mean body mass index 30.4 ± 5.4 kg/m(2) ] completed the trial. ancova showed a mean treatment effect [95% confidence interval (CI)] on HbA1c of -3.52 (-6.7 to -0.34) mmol/mol (p = .045). There was no difference in fasting glucose -4.7 mg/dL (95% CI -16.3 to 6.9; p = .426).
Vitamin D supplementation in obese hypertensive patients with low 25(OH)D reduces HbA1c levels. This finding warrants further investigation into potential vitamin D effects on glucose homeostasis.
研究维生素 D 补充对血糖控制的疗效。
施蒂里亚维生素 D 高血压试验是一项单中心、双盲、安慰剂对照研究，于 2011 年至 2014 年在奥地利格拉茨医科大学进行。我们招募了 200 名患有动脉高血压和 25-羟维生素 D [25(OH)D]浓度<30ng/ml 的患者。研究参与者被随机分配每天接受 2800IU 维生素 D 或安慰剂治疗 8 周。本研究是一项事后分析，采用协方差分析（ancova）方法，同时调整了基线差异。
共有 185 名参与者[平均±标准差年龄，60.1±11.3 岁；47%为女性；平均 25(OH)D 21.2±5.6ng/ml，平均糖化血红蛋白（HbA1c）44.8±11.8mmol/mol，平均体重指数 30.4±5.4kg/m2]完成了试验。ancova 显示 HbA1c 的平均治疗效果[95%置信区间（CI）]为-3.52（-6.7 至-0.34）mmol/mol（p=0.045）。空腹血糖无差异-4.7mg/dl（95%CI-16.3 至 6.9；p=0.426）。
在低 25(OH)D 的肥胖高血压患者中补充维生素 D 可降低 HbA1c 水平。这一发现值得进一步研究维生素 D 对葡萄糖稳态的潜在影响。
